Approved by the Board on: 15 November 2012
The Board refers to its decision (GF/B20/DP24) to review the findings of the Independent Evaluation of the Affordable Medicines Facility - malaria (AMFm) Phase 1 and make a recommendation on whether to "expand, accelerate, modify, terminate or suspend the AMFm business line" in pilot countries.
The Board decides to modify the existing AMFm business line by integrating the lessons learned from the operations and resourcing of Phase 1 of the AMFm into Global Fund grant management and financial processes by:
2013 Transition by AMFm Pilot Countries to Full Integration:
Related Decision Points2